Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorect...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Grasselli
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors J. Grasselli1, E. Elez1, G. Caratù2, J. Matito2, C. Santos3, T. Macarulla1, J. Vidal4, M. Garcia3, J.M. Viéitez5, D. Paéz6, E. Falcó7, C..L. Lopez8, E. Aranda9, F. Jones10, V. Sikri10, P. Nuciforo11, R. Dienstmann1, C. Montagut2, J. Tabernero1, D. Azuara12, R. Salazar3, A. Vivancos9
  • 1Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain, /
  • 2Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain, /
  • 3Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Spain, /
  • 4Department of Medical Oncology, Del Mar University Hospital, Barcelona, Spain, /
  • 5Department of Medical Oncology, Asturias University Hospital, Oviedo, Spain, /
  • 6Department of Medical Oncology, Santa Creu i Sant Pau University Hospital, Barcelona, Spain, /
  • 7Department of Medical Oncology, Son Llatzer University Hospital, Palma de Mallorca Spain, /
  • 8Department of Medical Oncology, Marques de Valdecilla University Hospital, Santander, Spain, /
  • 9Department of Medical Oncology, Reina Sofía University Hospital, Córdoba, Spain, /
  • 10Sysmex Inostics Inc., /
  • 11Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain, /
  • 12Traslational Research Laboratory, Catalan Institute of Oncology, L'Hospitalet, Spain, /

Abstract

Anti-EGFR monoclonal antibodies (MoAb) should only be considered for treatment of patients with colorectal cancer (CRC) whose tumors are wild-type (WT) for RAS genes. Determination of RAS status based on circulating tumor DNA (ctDNA) is expected to offer advantages over standard tissue testing. Validation of concordance between plasma and tissue determination is critical to move ctDNA forward as a surrogate testing in clinical practice.